Shortage of antiseizure medication in Germany: How big is the problem?

IF 2.3 3区医学 Q2 BEHAVIORAL SCIENCES

Epilepsy & Behavior Pub Date : 2024-11-29 DOI:10.1016/j.yebeh.2024.110162

Josephine Steidl , Sabine Krebs , Karel Kostev , Stefan Schwab , Hajo M. Hamer

{"title":"Shortage of antiseizure medication in Germany: How big is the problem?","authors":"Josephine Steidl , Sabine Krebs , Karel Kostev , Stefan Schwab , Hajo M. Hamer","doi":"10.1016/j.yebeh.2024.110162","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We determined the frequency of drug shortages of antiseizure medication (ASM) availability in Germany.</div></div><div><h3>Methods</h3><div>Retrospective and descriptive analysis of databases of 2 pharmaceutical wholesalers in Germany with a market share of about 45% of the German market in July 2023 (chosen arbitrarily) focusing on antiseizure drug shortages (i.e. demand could not be met entirely) and disruptions (i.e. demand could not be met at all) on the level of formulations, ASM and of manufacturers.</div></div><div><h3>Results</h3><div>98/909 (10.8%) of formulations of ASM with Wholesaler A were listed with drug shortages and 131/872 (15%) of formulations were reported with drug shortages at Wholesaler B. 19 of 222 (8.6%) entire ASM at Wholesaler A and 12/213 (5.6%) of ASM with Wholesaler B were reported with drug shortages. 41/62 (66.1%) manufacturers at wholesaler A and 36/57 (63.2%) manufacturers at wholesaler B reported shortages. The three compounds affected most frequently by drug shortages were pregabalin, levetiracetam and carbamazepine. 1.7% (Wholesaler A) and 12.9% (Wholesaler B) of formulations were listed with disruptions.</div><div>16.7% (40/239) of ASM with drug shortages/disruptions were brand-name ASM and 83.3% (199/239) were generic ASM.</div></div><div><h3>Conclusions</h3><div>11% to 15% of ASM formulations had drug shortages in Germany in July 2023. Generic ASM were more frequently affected than brand-name ASM. About 2/3 of manufacturers were reported to have drug shortages.</div></div>","PeriodicalId":11847,"journal":{"name":"Epilepsy & Behavior","volume":"162 ","pages":"Article 110162"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy & Behavior","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525505024005444","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

We determined the frequency of drug shortages of antiseizure medication (ASM) availability in Germany.

Methods

Retrospective and descriptive analysis of databases of 2 pharmaceutical wholesalers in Germany with a market share of about 45% of the German market in July 2023 (chosen arbitrarily) focusing on antiseizure drug shortages (i.e. demand could not be met entirely) and disruptions (i.e. demand could not be met at all) on the level of formulations, ASM and of manufacturers.

Results

98/909 (10.8%) of formulations of ASM with Wholesaler A were listed with drug shortages and 131/872 (15%) of formulations were reported with drug shortages at Wholesaler B. 19 of 222 (8.6%) entire ASM at Wholesaler A and 12/213 (5.6%) of ASM with Wholesaler B were reported with drug shortages. 41/62 (66.1%) manufacturers at wholesaler A and 36/57 (63.2%) manufacturers at wholesaler B reported shortages. The three compounds affected most frequently by drug shortages were pregabalin, levetiracetam and carbamazepine. 1.7% (Wholesaler A) and 12.9% (Wholesaler B) of formulations were listed with disruptions.

16.7% (40/239) of ASM with drug shortages/disruptions were brand-name ASM and 83.3% (199/239) were generic ASM.

Conclusions

11% to 15% of ASM formulations had drug shortages in Germany in July 2023. Generic ASM were more frequently affected than brand-name ASM. About 2/3 of manufacturers were reported to have drug shortages.

Abstract Image

查看原文本刊更多论文

德国抗癫痫药物短缺：问题有多大？

目的确定德国抗癫痫药物（ASM）可用性的药物短缺频率。方法对2023年7月德国市场份额约为45%的2家药品批发商（任意选择）的数据库进行回顾性和描述性分析，重点分析抗癫痫药物在配方、ASM和制造商层面的短缺（即需求无法完全满足）和中断（即需求根本无法满足）。结果A批发商销售的ASM中有98/909个（10.8%）制剂存在药品短缺，B批发商销售的ASM中有131/872个（15%）制剂存在药品短缺，A批发商销售的整个ASM中222个（8.6%）制剂中有19个存在药品短缺，B批发商销售的ASM中有12/213个（5.6%）制剂存在药品短缺。批发商A的41/62（66.1%）制造商和批发商B的36/57（63.2%）制造商报告短缺。最常受到药物短缺影响的三种化合物是普瑞巴林、左乙拉西坦和卡马西平。1.7%（批发商A）和12.9%（批发商B）的制剂出现了中断，16.7%（40/239）的ASM出现了药品短缺/中断，83.3%（199/239）为仿制药ASM。结论2023年7月，德国有11% ~ 15%的ASM制剂出现药品短缺。仿制ASM比品牌ASM更容易受到影响。据报道，约有三分之二的制造商药品短缺。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epilepsy & Behavior 医学-行为科学

CiteScore

5.40

自引率

15.40%

发文量

385

审稿时长

43 days

期刊介绍： Epilepsy & Behavior is the fastest-growing international journal uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy. Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging. From September 2012 Epilepsy & Behavior stopped accepting Case Reports for publication in the journal. From this date authors who submit to Epilepsy & Behavior will be offered a transfer or asked to resubmit their Case Reports to its new sister journal, Epilepsy & Behavior Case Reports.